Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation-Reference-Cited by-同舟云学术

Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation

Published:2020-09 Issue:9 Volume:20 Page:610-616
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Hua Jingsheng,Zhang Jian,Wu Xiaoxia,Zhou Lili,Bao Xiebing,Han Yue,Miao Miao,Li Caixia,Fu Zhengzheng,Wu Depei,Qian Weiqing,Qiu Huiying

Funder

National Natural Science Foundation of Jiangsu Province

Project of Invigorating Health Care through Science

Technology and Education

Jiangsu Provincial Key Medical Center

Priority Academic Program Development of Jiangsu Higher Education Institutions

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference34 articles.

1. The myth of the second remission of acute leukemia in the adult;Forman;Blood,2013

2. A single course of all-trans retinoic acid plus arsenic trioxide reached a long-term survival in a patient with newly diagnosed acute promyelocytic leukemia: a suggestion for reduction of treatment courses?

3. Second haploidentical peripheral blood stem cell transplantation for treatment of acute leukemia with relapse after first allogeneic peripheral blood stem cell transplantation;Yeh;Bone Marrow Transplant,2015

4. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation;Roddie;Expert Opin Biol Ther,2011

5. Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients;Huang;Best Pract Res Clin Haematol,2011

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation;Bone Marrow Transplantation;2023-07-29

2. Donor-derived CAR-T therapy improves the survival of relapsed B-ALL after allogeneic transplantation compared with donor lymphocyte infusion;Human Cell;2023-07-07

3. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant;Frontiers in Immunology;2023-07-04

4. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study;Frontiers in Immunology;2023-01-04

5. Long-term survival and immune reconstitution of chimeric antigen receptor T-cell therapy for childhood molecular relapse of B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation;2022-10-19